{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:19:05Z","timestamp":1792509545432,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Acid sphingomyelinase deficiency (ASMD) is a rare, progressive lysosomal storage disorder resulting from a deficiency in acid sphingomyelinase, leading to sphingomyelin accumulation and multi-organ damage. ASMD presents a broad phenotypic spectrum with a continuum of severity, making it challenging to predict the phenotype in very young children and differentiate between acute and chronic neurovisceral disease. No disease-specific treatments existed for ASMD. Recently, Olipudase-alfa, an intravenous enzyme replacement therapy, has been approved for non-neurological manifestations based on clinical trial results showing significant improvements. This report details the compassionate use of Olipudase-alfa in a 8-month-old boy. At baseline, he exhibited hepatosplenomegaly, elevated transaminases, and normal developmental milestones, consistent with a chronic neurovisceral phenotype. The treatment commenced at 8 months of age, escalating from 0.03\u2005mg\/kg to 3\u2005mg\/kg bi-weekly. Throughout the two-year period, the child tolerated the therapy well, with no severe adverse events reported. Notable clinical outcomes included a significant reduction in spleen and liver size, normalization of liver function tests, and stabilization of the lipid profile. The biomarker Lyso-sphingomyelin significantly reduced but never normalized, while oxysterols completely normalized. In the following months, the patient exhibited neurocognitive regression, allowing to define an acute neurovisceral phenotype. Although not impacting on the neurological manifestations, treatment with Olipudase-alfa strikingly improved the child's visceral symptoms, contrasting with the typical progressive decline seen in untreated patients. This report highlights the importance of early intervention, even in patients with neurovisceral phenotypes, as it can enhance quality of life for both patients and their families. Our findings advocate for reconsidering treatment eligibility criteria based solely on clinical phenotype definitions, highlighting the need for a tailored approach in ASMD management.<\/jats:p>","DOI":"10.3389\/fped.2024.1518344","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T02:01:13Z","timestamp":1736128873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Two years of compassionate use with Olipudase-alfa in a child with neurovisceral acid sphingomyelinase deficiency"],"prefix":"10.3389","volume":"12","author":[{"given":"Federica","family":"Deodato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Boenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Graziosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Dionisi-Vici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","article-title":"Types A and B Niemann\u2013Pick disease","volume":"120","author":"Schuchman","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/humu.22923","article-title":"SMPD1 mutation update: database and comprehensive analysis of published and novel variants","volume":"37","author":"Zampieri","year":"2016","journal-title":"Hum Mutat"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","article-title":"Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann\u2013Pick disease types A, B and A\/B)","volume":"18","author":"Geberhiwot","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","article-title":"A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results","volume":"24","author":"Wasserstein","year":"2022","journal-title":"Genet Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","article-title":"Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results","volume":"17","author":"Diaz","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12887-021-02756-3","article-title":"Normal sonographic liver and spleen dimensions in a central European pediatric population","volume":"21","author":"Waelti","year":"2021","journal-title":"BMC Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cca.2018.08.039","article-title":"The impact of biomarkers analysis in the diagnosis of Niemann\u2013Pick C disease and acid sphingomyelinase deficiency","volume":"486","author":"Deodato","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2023.100957","article-title":"Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: a single center experience in Taiwan","author":"Pan","year":"2023","journal-title":"Mol Genet Metab Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"107824","DOI":"10.1016\/j.ymgme.2023.107824","article-title":"Efficacy and safety of olipudase alfa in children: a real-life case report","volume":"141","author":"Teixeira","year":"2024","journal-title":"Mol Genet Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ophtha.2003.10.034","article-title":"Ocular manifestations of Niemann\u2013Pick disease type B","volume":"111","author":"McGovern","year":"2004","journal-title":"Ophthalmology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e33534","DOI":"10.7759\/cureus.33534","article-title":"Niemann-Pick disease: a case report and literature review","volume":"15","author":"V\u00e9lez Pinos","year":"2023","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1086\/345074","article-title":"The demographics and distribution of type B niemann-pick disease: novel mutations lead to new genotype\/phenotype correlations","volume":"71","author":"Simonaro","year":"2002","journal-title":"AJHG"},{"key":"B13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/cge.12076","article-title":"Identification of seven novel SMPD1 mutations causing Niemann\u2013Pick disease types A and B","volume":"84","author":"Irun","year":"2013","journal-title":"Clin Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/humu.9258","article-title":"Screening of 25 Italian patients with Niemann\u2013Pick A reveals fourteen new mutations, one common and thirteen private, in SMPD1","volume":"24","author":"Ricci","year":"2004","journal-title":"Hum Mutat"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mam.2009.02.005","article-title":"Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis","volume":"30","author":"Brown","year":"2009","journal-title":"Mol Aspects Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","article-title":"Natural history of type A Niemann\u2013Pick disease: possible endpoints for therapeutic trials","volume":"66","author":"McGovern","year":"2006","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12876-022-02310-0","article-title":"Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/gim.2017.7","article-title":"Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency","volume":"19","author":"McGovern","year":"2017","journal-title":"Genet Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","article-title":"Revised recommendations for the management of gaucher disease in children","volume":"172","author":"Kaplan","year":"2013","journal-title":"Eur J Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of type 2 gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol Genet Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-024-03020-4","article-title":"Real-life impacts of olipudase alfa: the experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency","volume":"19","author":"Raebel","year":"2024","journal-title":"Orphanet J Rare Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1518344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T02:01:15Z","timestamp":1736128875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1518344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":22,"alternative-id":["10.3389\/fped.2024.1518344"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1518344","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1518344"}}